Biomedical subjects

F Bonichon

Publications and source records attributed to F Bonichon.

96 records · Page 6Linked to original sources

PubMedDate not supplied

[Radiotherapy of stage T1-T2 M0 prostatic adenocarcinoma. Analysis of the carcinologic results of a multicenter study of 610 patients. Groupe Radiothérapie de la Commission de Coopération Médicale Intercentres (CCMI)].

PURPOSE: Retrospective analysis of the results of radiotherapy in localized prostatic adenocarcinoma. Complications were excluded. PATIENTS AND METHODS: Six-hundred-and-ten T1-T2 adenocarcinomas of the prostate were treated with continuous courses of external beam radiation therapy in 19 participating Institutes between January 1983 and January 1988. The mean follow-up was 10.4 years; the mean age of patients at the beginning of radiotherapy was 68.5 years. RESULTS: A 10-year, local control had been achieved in 86% of T1-T2 (81.4% for T2). The 5- and 10-year metastatic relapse rates were 25.3% and 30% (29% and 38.1% for T2), respectively. At 10 years, 62.4% of T1-T2 were recurrence-free; overall survival rate was 45.8% and cause-specific survival rate was 70.5%; 29.9% of T1-T2 patients were alive and disease-free. T category (TNM), pathologic grade, pelvic lymph node status, local tumor control, and obstructive ureteral symptoms were correlated with survival. The influence of pelvic nodes radiation, dose, overall treatment time, previous endocrine treatment, and transuretral resection was not significant for disease-free survival (alive and disease-free) and other endpoints. CONCLUSION: There was no difference between the French series (1975-1982 and 1983-1988). The results of the literature are comparable to ours. As far as prognostic factors are concerned, this report provides evidence that the explainable variables which influence survival depend on the tumor and patient status.

Adenocarcinoma↗

PubMedDate not supplied

[Course of follicular lymphomas in a series of 281 patients].

From 1963 to 1988, 281 patients suffering follicular lymphomas and without previous treatment were treated in the same institution. One hundred and thirty three had a localized disease (72 stages I, 61 stages II) ans 148 an extended disease (83 stages III and 85 stages IV). In the absence of dramatic therapeutic improvement quite all patients were treated in a homogeneous manner with radical radiotherapy for localized disease and palliative chemotherapy for extended ones. Median follow-up is 9 years. Ten year overall survival is 38% and relapse free survival 29.5%. Multivariate analysis show two main prognosis factors: age (+ or - 60 years) and tumoral mass (as shown by stage or number of involved area). Survival depends also on complete remission. Age and tumoral mass allows us to define three prognosis groups: favorable, intermediate, unfavorable. These groups justify different therapeutic approach and different proposals for prospective therapeutic trials.

Age Factors↗

PubMedDate not supplied

[Results of assays of estrogen, progesterone and androgen receptors in stage I and II adenocarcinoma of the endometrium].

The prognosis for adenocarcinoma of the endometrium is dependent on the findings of the histopathological assessment of the tumor. In a retrospective study of patients treated in initially by surgery, the estrogen and progesterone receptors were assayed 89 times and the androgen receptors 64 times. No statistically significant correlation was found between any of these receptors and the degree of structural differentiation or degree of infiltration of the myometrium. The absence of any one of these receptors had no negative impact on the overall survival nor on recurrence-free survival. The same was true for the 9 tumors which were devoid of both estrogen and progesterone receptors. In the authors' experience, the results of these hormone assays did not provide any further information on which to base the prognosis of endometrial cancers.

Adenocarcinoma↗

PubMedDate not supplied

[Home parenteral nutrition in oncology, a information project].

The increase in the indications for total parenteral nutrition (TPN) of long or medium term duration led to an investigation on a discontinued method during the night. The patient was thus free during the daytime. Cyclic parenteral nutrition (CPN) at home is a comfortable solution. Parenteral nutrition at home (PNH) enables the quality of life to be improved and also reduces the cost of the therapy, which may permit us to establish a structure for oncological patients to take advantage of PNH. In the specific case of oncology, we shall examine in the first place, the conditions, indications and counter indications, complications, advantages and structure operation. To improve on this method, we have introduced a data processing system that provides the doctor with more autonomy and assists in caring for the patient and in the therapeutical decision.

Contraindications↗

PubMedDate not supplied

[The request for surgical biopsy in mammography. Apropos of 140 verified cases].

The authors present a series of 140 patients who underwent surgical biopsy guided by an isolated anomaly on mammography without any clinical sign. 27 cases presented an opacity with a long axis less than 10 mm, 59 cases presented isolated areas of micro-calcification and 54 cases presented images of focal distorsion of the glandular architecture. By means of pre- and intra-operative radiographic guidance, the histological analysis of serial sections of these abnormalities was possible in every case, resulting in the diagnosis of 54 cases of benign dysplasia, 31 transitional lesion, including 16 in situ carcinomas and 55 carcinomas, including 34 invasive cancers. The advantage and limitations of this diagnostic approach are analysed. The discovery of a large number of sub-clinical carcinomas, the favourable implications for preservation of the breast and the survival justify the indications for surgical biopsy on the discovery of an isolated mammographic abnormality.

Biopsy↗

PubMedDate not supplied

[Standards, options and diagnostic and therapeutic recommendations in oncology. Fédération Nationale des Centres de Lutte contre le Cancer].

From 1992 onwards, the various French institutions working on cancerology launched a program for establishing standards and options in view of assisting practitioners. The program is basically oriented towards diagnostics and care, but economic, social or ethical aspects are not neglected. A first edition of the recommended standards and options was published in 1995 on paper and CD-ROM. Dissemination through Internet is planned.

Humans↗